GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (NAS:RSLS) » Definitions » Change In Working Capital

RSLS (Reshape Lifesciences) Change In Working Capital : $2.39 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Change In Working Capital?

Reshape Lifesciences's change in working capital for the quarter that ended in Dec. 2024 was $0.67 Mil.

Reshape Lifesciences's change in working capital for the fiscal year that ended in Dec. 2024 was $2.39 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).


Reshape Lifesciences Change In Working Capital Historical Data

The historical data trend for Reshape Lifesciences's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Change In Working Capital Chart

Reshape Lifesciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -2.71 0.71 -4.13 2.39

Reshape Lifesciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Change In Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.76 0.45 0.26 1.00 0.67

Reshape Lifesciences Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.39 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reshape Lifesciences Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences Business Description

Traded in Other Exchanges
N/A
Address
18 Technology Drive, Suite 110, Irvine, CA, USA, 92618
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
Executives
Thomas Stankovich officer: Chief Financial Officer 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Paul F. Hickey director, officer: President and CEO 2800 PATTON ROAD, ST. PAUL MN 55113
Barton P. Bandy director 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Mcdougal Lori Courtney director 2800 PATTON ROAD, ST. PAUL MN 55113
Arda Phd Minocherhomjee director C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Dan W Gladney director 2800 PATTON ROAD, ST. PAUL MN 55113
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Gary Blackford director 7700 FRANCE AVENUE SOUTH, EDINA MN 55435
Robert J Macdonald officer: Chief Retail Officer C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Daina Schmidt officer: Vice President of Marketing C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Gilbert H Kliman 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Arnold L Oronsky 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Khaled Nasr 10 percent owner 467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022
Interwest Partners X Lp 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022